CovidStanfordV1, Main, Exploration, bibRecord, 000798

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.

Identifieur interne : 000798 ( Main/Exploration ); précédent : 000797; suivant : 000799

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.

Auteurs : Fabian Sanchis-Gomar [États-Unis] ; Carl J. Lavie [États-Unis] ; Carme Perez-Quilis [Espagne] ; Brandon M. Henry [États-Unis] ; Giuseppe Lippi [Italie]

Source :

Mayo Clinic proceedings [ 1942-5546 ] ; 2020.

RBID : pubmed:32376099

Descripteurs français

KwdFr :
- Antagonistes des récepteurs aux angiotensines (pharmacologie), Betacoronavirus (isolement et purification), Comorbidité (MeSH), Humains (MeSH), Hypertension artérielle (métabolisme), Hypertension artérielle (traitement médicamenteux), Hypertension artérielle (épidémiologie), Infections à coronavirus (métabolisme), Infections à coronavirus (épidémiologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie), Pandémies (MeSH), Peptidyl-Dipeptidase A (métabolisme), Pneumopathie virale (métabolisme), Pneumopathie virale (épidémiologie), Système rénine-angiotensine (effets des médicaments et des substances chimiques), Sélection de patients (MeSH).
MESH :
- effets des médicaments et des substances chimiques : Système rénine-angiotensine.
- isolement et purification : Betacoronavirus.
- métabolisme : Hypertension artérielle, Infections à coronavirus, Peptidyl-Dipeptidase A, Pneumopathie virale.
- pharmacologie : Antagonistes des récepteurs aux angiotensines, Inhibiteurs de l'enzyme de conversion de l'angiotensine.
- traitement médicamenteux : Hypertension artérielle.
- épidémiologie : Hypertension artérielle, Infections à coronavirus, Pneumopathie virale.
- Comorbidité, Humains, Pandémies, Sélection de patients.

English descriptors

KwdEn :
- Angiotensin Receptor Antagonists (pharmacology), Angiotensin-Converting Enzyme 2 (MeSH), Angiotensin-Converting Enzyme Inhibitors (pharmacology), Betacoronavirus (isolation & purification), COVID-19 (MeSH), Comorbidity (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (metabolism), Humans (MeSH), Hypertension (drug therapy), Hypertension (epidemiology), Hypertension (metabolism), Pandemics (MeSH), Patient Selection (MeSH), Peptidyl-Dipeptidase A (metabolism), Pneumonia, Viral (epidemiology), Pneumonia, Viral (metabolism), Renin-Angiotensin System (drug effects), SARS-CoV-2 (MeSH).
MESH :
- chemical , metabolism : Peptidyl-Dipeptidase A.
- chemical , pharmacology : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors.
- chemical : Angiotensin-Converting Enzyme 2.
- drug effects : Renin-Angiotensin System.
- drug therapy : Hypertension.
- epidemiology : Coronavirus Infections, Hypertension, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- metabolism : Coronavirus Infections, Hypertension, Pneumonia, Viral.
- COVID-19, Comorbidity, Humans, Pandemics, Patient Selection, SARS-CoV-2.

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking antihypertensive medications as prescribed without interruption. Because ACEIs and ARBs are also used to retard the progression of chronic kidney disease, we suggest that these recommendations also apply to the use of these agents in chronic kidney disease. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing blood pressure and improving other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. The ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, and withdrawal rates due to adverse events are lower with ARBs. Given their equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in patients with COVID-19 at higher risk for severe forms of disease.

DOI: 10.1016/j.mayocp.2020.03.026
PubMed: 32376099
PubMed Central: PMC7129862

Affiliations:

Espagne, Italie, États-Unis
Californie, Louisiane, Ohio

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000754
to stream Main, to step Curation: 000754

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.</title>
<author><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain; Division of Cardiovascular Medicine, Stanford University School of Medicine, CA. Electronic address: fabian.sanchis@uv.es.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain; Division of Cardiovascular Medicine, Stanford University School of Medicine</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lavie, Carl J" sort="Lavie, Carl J" uniqKey="Lavie C" first="Carl J" last="Lavie">Carl J. Lavie</name>
<affiliation wicri:level="2"><nlm:affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Louisiane</region>
</placeName>
<wicri:cityArea>John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Perez Quilis, Carme" sort="Perez Quilis, Carme" uniqKey="Perez Quilis C" first="Carme" last="Perez-Quilis">Carme Perez-Quilis</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute</wicri:regionArea>
<wicri:noRegion>University of Valencia and INCLIVA Biomedical Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Henry, Brandon M" sort="Henry, Brandon M" uniqKey="Henry B" first="Brandon M" last="Henry">Brandon M. Henry</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiac Intensive Care Unit, Heart Institute, Cincinnati Children's Hospital Medical Center, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cardiac Intensive Care Unit, Heart Institute, Cincinnati Children's Hospital Medical Center</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lippi, Giuseppe" sort="Lippi, Giuseppe" uniqKey="Lippi G" first="Giuseppe" last="Lippi">Giuseppe Lippi</name>
<affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Biochemistry, University of Verona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Clinical Biochemistry, University of Verona</wicri:regionArea>
<wicri:noRegion>University of Verona</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32376099</idno>
<idno type="pmid">32376099</idno>
<idno type="doi">10.1016/j.mayocp.2020.03.026</idno>
<idno type="pmc">PMC7129862</idno>
<idno type="wicri:Area/Main/Corpus">000754</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000754</idno>
<idno type="wicri:Area/Main/Curation">000754</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000754</idno>
<idno type="wicri:Area/Main/Exploration">000754</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.</title>
<author><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain; Division of Cardiovascular Medicine, Stanford University School of Medicine, CA. Electronic address: fabian.sanchis@uv.es.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain; Division of Cardiovascular Medicine, Stanford University School of Medicine</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lavie, Carl J" sort="Lavie, Carl J" uniqKey="Lavie C" first="Carl J" last="Lavie">Carl J. Lavie</name>
<affiliation wicri:level="2"><nlm:affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Louisiane</region>
</placeName>
<wicri:cityArea>John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Perez Quilis, Carme" sort="Perez Quilis, Carme" uniqKey="Perez Quilis C" first="Carme" last="Perez-Quilis">Carme Perez-Quilis</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute</wicri:regionArea>
<wicri:noRegion>University of Valencia and INCLIVA Biomedical Research Institute</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Henry, Brandon M" sort="Henry, Brandon M" uniqKey="Henry B" first="Brandon M" last="Henry">Brandon M. Henry</name>
<affiliation wicri:level="2"><nlm:affiliation>Cardiac Intensive Care Unit, Heart Institute, Cincinnati Children's Hospital Medical Center, OH.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Ohio</region>
</placeName>
<wicri:cityArea>Cardiac Intensive Care Unit, Heart Institute, Cincinnati Children's Hospital Medical Center</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lippi, Giuseppe" sort="Lippi, Giuseppe" uniqKey="Lippi G" first="Giuseppe" last="Lippi">Giuseppe Lippi</name>
<affiliation wicri:level="1"><nlm:affiliation>Section of Clinical Biochemistry, University of Verona, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Section of Clinical Biochemistry, University of Verona</wicri:regionArea>
<wicri:noRegion>University of Verona</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Mayo Clinic proceedings</title>
<idno type="eISSN">1942-5546</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (pharmacology)</term>
<term>Angiotensin-Converting Enzyme 2 (MeSH)</term>
<term>Angiotensin-Converting Enzyme Inhibitors (pharmacology)</term>
<term>Betacoronavirus (isolation & purification)</term>
<term>COVID-19 (MeSH)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (metabolism)</term>
<term>Humans (MeSH)</term>
<term>Hypertension (drug therapy)</term>
<term>Hypertension (epidemiology)</term>
<term>Hypertension (metabolism)</term>
<term>Pandemics (MeSH)</term>
<term>Patient Selection (MeSH)</term>
<term>Peptidyl-Dipeptidase A (metabolism)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (metabolism)</term>
<term>Renin-Angiotensin System (drug effects)</term>
<term>SARS-CoV-2 (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (pharmacologie)</term>
<term>Betacoronavirus (isolement et purification)</term>
<term>Comorbidité (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Hypertension artérielle (métabolisme)</term>
<term>Hypertension artérielle (traitement médicamenteux)</term>
<term>Hypertension artérielle (épidémiologie)</term>
<term>Infections à coronavirus (métabolisme)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (pharmacologie)</term>
<term>Pandémies (MeSH)</term>
<term>Peptidyl-Dipeptidase A (métabolisme)</term>
<term>Pneumopathie virale (métabolisme)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Système rénine-angiotensine (effets des médicaments et des substances chimiques)</term>
<term>Sélection de patients (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Peptidyl-Dipeptidase A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Angiotensin Receptor Antagonists</term>
<term>Angiotensin-Converting Enzyme Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Angiotensin-Converting Enzyme 2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Renin-Angiotensin System</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Hypertension</term>
</keywords>
<keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Système rénine-angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term>
<term>Hypertension</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Peptidyl-Dipeptidase A</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term>
<term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Hypertension artérielle</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Hypertension artérielle</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Comorbidity</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Patient Selection</term>
<term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Comorbidité</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Sélection de patients</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking antihypertensive medications as prescribed without interruption. Because ACEIs and ARBs are also used to retard the progression of chronic kidney disease, we suggest that these recommendations also apply to the use of these agents in chronic kidney disease. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing blood pressure and improving other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. The ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, and withdrawal rates due to adverse events are lower with ARBs. Given their equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in patients with COVID-19 at higher risk for severe forms of disease.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32376099</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>16</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>27</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1942-5546</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>95</Volume>
<Issue>6</Issue>
<PubDate><Year>2020</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>Mayo Clinic proceedings</Title>
<ISOAbbreviation>Mayo Clin Proc</ISOAbbreviation>
</Journal>
<ArticleTitle>Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.</ArticleTitle>
<Pagination><MedlinePgn>1222-1230</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0025-6196(20)30315-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mayocp.2020.03.026</ELocationID>
<Abstract><AbstractText>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, is being defined as the worst pandemic disease of modern times. Several professional health organizations have published position papers stating that there is no evidence to change the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the management of elevated blood pressure in the context of avoiding or treating COVID-19 infection. In this article, we review the evidence on the relationship between the renin-angiotensin-aldosterone system and COVID-19 infection. In agreement with current guidelines, patients with hypertension should continue taking antihypertensive medications as prescribed without interruption. Because ACEIs and ARBs are also used to retard the progression of chronic kidney disease, we suggest that these recommendations also apply to the use of these agents in chronic kidney disease. No differences generally exist between ARBs and ACEIs in terms of efficacy in decreasing blood pressure and improving other outcomes, such as all-cause mortality, cardiovascular mortality, myocardial infarction, heart failure, stroke, and end-stage renal disease. The ACEIs are associated with cough secondary to accumulation of bradykinin and angioedema, and withdrawal rates due to adverse events are lower with ARBs. Given their equal efficacy but fewer adverse events, ARBs could potentially be a more favorable treatment option in patients with COVID-19 at higher risk for severe forms of disease.</AbstractText>
<CopyrightInformation>Copyright © 2020. Published by Elsevier Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchis-Gomar</LastName>
<ForeName>Fabian</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain; Division of Cardiovascular Medicine, Stanford University School of Medicine, CA. Electronic address: fabian.sanchis@uv.es.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lavie</LastName>
<ForeName>Carl J</ForeName>
<Initials>CJ</Initials>
<AffiliationInfo><Affiliation>John Ochsner Heart and Vascular Institute, Ochsner Clinical School-The University of Queensland School of Medicine, New Orleans, LA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Perez-Quilis</LastName>
<ForeName>Carme</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, University of Valencia and INCLIVA Biomedical Research Institute, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Henry</LastName>
<ForeName>Brandon M</ForeName>
<Initials>BM</Initials>
<AffiliationInfo><Affiliation>Cardiac Intensive Care Unit, Heart Institute, Cincinnati Children's Hospital Medical Center, OH.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lippi</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
<AffiliationInfo><Affiliation>Section of Clinical Biochemistry, University of Verona, Italy.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Mayo Clin Proc</MedlineTA>
<NlmUniqueID>0405543</NlmUniqueID>
<ISSNLinking>0025-6196</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.15.1</RegistryNumber>
<NameOfSubstance UI="D007703">Peptidyl-Dipeptidase A</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber>
<NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Mayo Clin Proc. 2020 Jul;95(7):1552-1553</RefSource>
<PMID Version="1">32622456</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Mayo Clin Proc. 2020 Jul;95(7):1553-1556</RefSource>
<PMID Version="1">32622458</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Mayo Clin Proc. 2020 Nov;95(11):2559-2561</RefSource>
<PMID Version="1">33153642</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Mayo Clin Proc. 2020 Nov;95(11):2561-2563</RefSource>
<PMID Version="1">33153643</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="Y">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006973" MajorTopicYN="Y">Hypertension</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007703" MajorTopicYN="N">Peptidyl-Dipeptidase A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="Y">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012084" MajorTopicYN="N">Renin-Angiotensin System</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>17</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32376099</ArticleId>
<ArticleId IdType="pii">S0025-6196(20)30315-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.mayocp.2020.03.026</ArticleId>
<ArticleId IdType="pmc">PMC7129862</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Physiol Genomics. 2006 Oct 3;27(1):12-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16788004</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Europace. 2017 Aug 1;19(8):1280-1287</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27738071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2006 Apr 4;78(19):2166-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16303146</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Mar 28;395(10229):1054-1062</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171076</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2014 Dec;64(6):1368-1375</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25225202</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 16;6:14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194980</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2020 May 21;526(1):135-140</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32199615</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci Rep. 2016 Jan 27;6:19840</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26813885</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Med. 2020 Apr;14(2):185-192</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32170560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viral Immunol. 2008 Jun;21(2):153-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18433331</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Mar 13;367(6483):1260-1263</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32075877</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2005 Feb;26(4):369-75; discussion 322-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15671045</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Nephrol Hypertens. 2016 Sep;25(5):384-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27367913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Sci (Lond). 2012 Oct;123(8):519-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22616805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Transl Med. 2020 Apr;8(7):497</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32395541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32165541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Physiol Rep. 2019 Jun;7(11):e14105</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31165585</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2004 May;43(5):970-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15007027</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2002 Jun 20;417(6891):822-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12075344</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur Heart J. 2020 May 14;41(19):1801-1803</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32196087</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2020 Mar 17;94(7):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31996437</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Mar 12;368:m1036</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32165426</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8258-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12829792</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Pathol. 2004 Jun;203(2):631-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15141377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circ Res. 2000 Sep 1;87(5):E1-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10969042</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Pept. 2012;2012:256294</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22536270</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Sci (Lond). 2012 Dec;123(11):649-58</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22715807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29598869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2003 Oct;42(4):574-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12953014</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2018 Jun 13;13(6):e0198144</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29897923</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Mol Cell Cardiol. 2014 Jan;66:167-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24332999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Circulation. 2005 May 24;111(20):2605-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15897343</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Physiol. 2011 Mar;96(3):287-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21148624</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Cell Mol Med. 2015 Aug;19(8):1965-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25766467</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hypertension. 2006 Oct;48(4):572-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16908757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Sci China Life Sci. 2020 Mar;63(3):364-374</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32048163</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Feb 28;368:m810</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32111649</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Physiol Renal Physiol. 2009 Feb;296(2):F398-405</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19004932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Aug;11(8):875-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16007097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2020 Jul;75(7):1730-1741</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Apr;8(4):e21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Dev Res. 2020 Aug;81(5):537-540</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32129518</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2017 Dec 13;21(1):305</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29237475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Oral Sci. 2020 Feb 24;12(1):8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Pharmacol Sci. 2004 Jun;25(6):291-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15165741</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Hypertens. 2020 May;38(5):781-782</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32195824</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2019 Mar 7;14(3):e0213096</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30845246</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Cardiol. 2020 May;17(5):259-260</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32139904</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Espagne</li>
<li>Italie</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Louisiane</li>
<li>Ohio</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Sanchis Gomar, Fabian" sort="Sanchis Gomar, Fabian" uniqKey="Sanchis Gomar F" first="Fabian" last="Sanchis-Gomar">Fabian Sanchis-Gomar</name>
</region>
<name sortKey="Henry, Brandon M" sort="Henry, Brandon M" uniqKey="Henry B" first="Brandon M" last="Henry">Brandon M. Henry</name>
<name sortKey="Lavie, Carl J" sort="Lavie, Carl J" uniqKey="Lavie C" first="Carl J" last="Lavie">Carl J. Lavie</name>
</country>
<country name="Espagne"><noRegion><name sortKey="Perez Quilis, Carme" sort="Perez Quilis, Carme" uniqKey="Perez Quilis C" first="Carme" last="Perez-Quilis">Carme Perez-Quilis</name>
</noRegion>
</country>
<country name="Italie"><noRegion><name sortKey="Lippi, Giuseppe" sort="Lippi, Giuseppe" uniqKey="Lippi G" first="Giuseppe" last="Lippi">Giuseppe Lippi</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000798 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000798 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32376099
   |texte=   Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32376099" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki